# Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.

Study · id `cardio:ct-nct05879276` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05879276](<https://clinicaltrials.gov/study/NCT05879276>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05879276

Browse, organ or system: Heart  
Browse, condition area: Heart failure; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 164 participants.

## Technical summary

Registry record NCT05879276. Randomized; no masking; primary purpose treatment. Start 2024-12-16 (actual); primary completion 2027-03-16 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 164 participants (planned count; ClinicalTrials.gov record NCT05879276, source copy `cardio:ctgov-nct05879276-2025-06-27`, retrieved 2026-10-26)
- Started: 2024-12-16 (actual) (ClinicalTrials.gov record NCT05879276, source copy `cardio:ctgov-nct05879276-2025-06-27`, retrieved 2026-10-26)
- Primary completion: 2027-03-16 (anticipated) (ClinicalTrials.gov record NCT05879276, source copy `cardio:ctgov-nct05879276-2025-06-27`, retrieved 2026-10-26)
- Completion: 2027-03-16 (anticipated) (ClinicalTrials.gov record NCT05879276, source copy `cardio:ctgov-nct05879276-2025-06-27`, retrieved 2026-10-26)
- Countries: France (ClinicalTrials.gov record NCT05879276, source copy `cardio:ctgov-nct05879276-2025-06-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05879276-2025-06-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.
- Acronym: EMPASHOCK
- Condition: Cardiogenic Shock
- Intervention (Drug): Empagliflozin 10 MG
- Lead sponsor: Central Hospital, Nancy, France
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Cardiogenic shock (`cardio:cardiogenic-shock`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Empagliflozin (`cardio:empagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: Central Hospital, Nancy, France (`cardio:org-central-hospital-nancy-france`)

## Provenance

Content hash: 8403ed852c52cf68787f5778a3e1774e2e8184543616c712e5b1f9efa8a8a9ab
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
